Our proprietary PCR-based in vitro molecular diagnostics assays, SensiScreen® and PlentiPlex™, for detection of somatic mutations in solid and liquid biopsies offers sensitive and ease-of-hand use. Based on PentaBase’s novel and selective INA® technologies SensiScreen® and PlentiPlex™ provide complementary diagnostics and monitoring of key disease gene mutations; including BRAF, KRAS, EGFR, NRAS, KIT, MYD88 and PIK3CA.
Our proprietary real-time PCR-based SensiScreen® and PlentiPlex™ MYD88 L265P assays for somatic mutation detection in cancer patients combine ultra-high sensitivity with multiplexing capabilities, speed, ease-of-use and little hands-on-time. Complementary diagnostics and monitoring of key cancer genes in solid and liquid biopsies.
PlentiPlex™ MSI assays for in vitro diagnosis of impaired mismatch repair (MMR) affecting prognosis and selection of treatment in cancer patients. The PlentiPlex™ MSI assays offer length analysis of five multiplexed microsatellite loci recommended by the Bethesda and Hamelin guidelines.
Mastocytosis is a disorder characterized by growth and accumulation of neoplastic mast cells within various organs and most commonly the skin. PlentiPlex™ Mastocytosis assay is designed to identify the presence of the KIT D816V mutation in mast cells to assist the diagnosis of mastocytosis.